First AD

Second AD

Panelists discuss how, PDS0101 uses Versamune® lipid nanoparticles to deliver HPV16 antigens, activating T-cells. Early Phase 2 data with pembrolizumab showed promise in HPV16+ head & neck cancer patients.

Updates From VERSATILE-002: Pembrolizumab Plus PDS0101 (HPV-16–Targeted Cancer Vaccine) in HPV-Positive HNSCC 

Video content above is prompted by the following:

Please describe the mechanism of action of the novel Versamune (PDS0101) HPV-16 targeted cancer vaccine.

Please discuss the recent data presented for the Phase 2 VERSATILE-002 study of PDS0101 + pembrolizumab in adults with HPV16 and PD-L1 positive recurrent/metastatic HNSCC.

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Video Series

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Exploring the Role of a Novel HPV16-Targeted Cancer T-cell Stimulating Immunotherapy (TSI) (Versamune® HPV) for Human Papilloma Virus (HPV) Positive Head and Neck Cancer (HNSCC)